Shopping Cart 0
Cart Subtotal
USD 0

Cancer Screening Market in China (2018-2023)

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 1950
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Cancer screening market in China

China's demand for cancer screening has grown at a fast pace in the past decade. Cancer is one of the most significant healthcare burdens in China. The Chinese economy maintains a high pace of growth stimulated by the consecutive increase in capital investment. The cancer screening market in China is expected to reach USD 1.5 Bn by 2023 at 14 % CAGR.

The cancer screening market in China is classified by end users, screening type and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal cancer.

Key growth factors

Rise in the population along with an increase in the patient pool and favourable government policies is a key driver for the market. Also, there is an increase in the aging population, growing levels of pollution and a more sedentary lifestyle.

Threats and key players

Providing drugs at lower prices along with ensuring affordability as well as accessibility will be a major threat for the region. Transparency in medical treatment is being been demanded by people, hence, provision of accurate and proper treatment will be a disguised opportunity.

The key players operating in the valve market are Quest Diagnostics, Hologic Inc., Qiagen, F. Hoffmann-La Roche AG and Abbott Laboratories.

What is covered in the report?

1. Overview of the cancer screening market in China.

2. Market drivers and challenges in the cancer screening market in China.

3. Market trends in the cancer screening market in China.

4. Historical, current and forecasted market size data for segments based on end users (hospitals, Laboratories, and independent physicians and clinics).

5. Historical, current and forecasted market size data for segments based on screening type (Laboratory, genetic, biopsy, imaging and endoscopy testing).

6. Historical, current and forecasted market size data for segmentation based on application (lung, breast, melanoma, kidney and colorectal cancer).

7. Analysis of the competitive landscape and profiles of the major companies operating in the market.

Why buy?

o Understand the demand for cancer screening market in China to determine the viability of the market.

o Identify the developed and emerging markets where cancer screening market in China is sold.

o Identify the challenge areas and address them.

o Develop strategies based on the drivers, trends and highlights for each of the segments.

o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.

o Recognize the key competitors of this market and respond accordingly.

o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.

o Define the competitive positioning by comparing the products and services with the key players in the market.

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.

READ MORE

Table Of Content

Scope

Chapter 1: Executive summary

1.1 Market scope and segmentation

1.2 Key questions answered in this study

1.3 Executive summary

Chapter 2: Cancer screening market in China-market overview

2.1. China market overview-market trends, market attractiveness analysis, geography-wise market revenue (USD)

2.2. China-market drivers and challenges

2.3. Value chain analysis-industrial valve market in China

2.4. Porter's five forces analysis

Chapter 3. Cancer screening market in China-by end users

3.1. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. Laboratories-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. Independent physicians and clinics-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 4. Cancer screening market in China-by screening type

4.1. Laboratory testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. Genetic testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. Imaging testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. Biopsy testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.5. Endoscopy testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 5. Cancer screening market in China-by application

5.1. Lung cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. Breast cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. Melanoma cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. Kidney cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.5. Colorectal cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 6: Competitive landscape

6.1. Quest Diagnostics (*)

6.1. a. Company snapshot

6.1. b. Product offerings

6.1. c. Growth strategies

6.1. d. Initiatives

6.1. e. Geographical presence

6.1. f. Key numbers

6.2. Hologic Inc.

6.3. Qiagen

6.4. F. Hoffmann-La Roche AG

6.5. Abbott Laboratories

(*) all the information are similar for the mentioned companies

Chapter 7: Conclusion

Chapter 8: Appendix

8.1. List of tables

8.2. Assumptions

8.3. Research and methodology

8.4. About Netscribes Inc.

Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research. Disclaimer: The report will be delivered within 5-7 business days post payment confirmation

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

1. Quest Diagnostics

2. Hologic Inc.

3. Qiagen

4. F. Hoffmann-La Roche AG

5. Abbott Laboratories

Cancer screening market in China

China's demand for cancer screening has grown at a fast pace in the past decade. Cancer is one of the most significant healthcare burdens in China. The Chinese economy maintains a high pace of growth stimulated by the consecutive increase in capital investment. The cancer screening market in China is expected to reach USD 1.5 Bn by 2023 at 14 % CAGR.

The cancer screening market in China is classified by end users, screening type and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal cancer.

Key growth factors

Rise in the population along with an increase in the patient pool and favourable government policies is a key driver for the market. Also, there is an increase in the aging population, growing levels of pollution and a more sedentary lifestyle.

Threats and key players

Providing drugs at lower prices along with ensuring affordability as well as accessibility will be a major threat for the region. Transparency in medical treatment is being been demanded by people, hence, provision of accurate and proper treatment will be a disguised opportunity.

The key players operating in the valve market are Quest Diagnostics, Hologic Inc., Qiagen, F. Hoffmann-La Roche AG and Abbott Laboratories.

What is covered in the report?

1. Overview of the cancer screening market in China.

2. Market drivers and challenges in the cancer screening market in China.

3. Market trends in the cancer screening market in China.

4. Historical, current and forecasted market size data for segments based on end users (hospitals, Laboratories, and independent physicians and clinics).

5. Historical, current and forecasted market size data for segments based on screening type (Laboratory, genetic, biopsy, imaging and endoscopy testing).

6. Historical, current and forecasted market size data for segmentation based on application (lung, breast, melanoma, kidney and colorectal cancer).

7. Analysis of the competitive landscape and profiles of the major companies operating in the market.

Why buy?

o Understand the demand for cancer screening market in China to determine the viability of the market.

o Identify the developed and emerging markets where cancer screening market in China is sold.

o Identify the challenge areas and address them.

o Develop strategies based on the drivers, trends and highlights for each of the segments.

o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.

o Recognize the key competitors of this market and respond accordingly.

o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.

o Define the competitive positioning by comparing the products and services with the key players in the market.

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.

READ MORE

Scope

Chapter 1: Executive summary

1.1 Market scope and segmentation

1.2 Key questions answered in this study

1.3 Executive summary

Chapter 2: Cancer screening market in China-market overview

2.1. China market overview-market trends, market attractiveness analysis, geography-wise market revenue (USD)

2.2. China-market drivers and challenges

2.3. Value chain analysis-industrial valve market in China

2.4. Porter's five forces analysis

Chapter 3. Cancer screening market in China-by end users

3.1. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. Laboratories-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. Independent physicians and clinics-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 4. Cancer screening market in China-by screening type

4.1. Laboratory testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. Genetic testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. Imaging testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. Biopsy testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.5. Endoscopy testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 5. Cancer screening market in China-by application

5.1. Lung cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. Breast cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. Melanoma cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. Kidney cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.5. Colorectal cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 6: Competitive landscape

6.1. Quest Diagnostics (*)

6.1. a. Company snapshot

6.1. b. Product offerings

6.1. c. Growth strategies

6.1. d. Initiatives

6.1. e. Geographical presence

6.1. f. Key numbers

6.2. Hologic Inc.

6.3. Qiagen

6.4. F. Hoffmann-La Roche AG

6.5. Abbott Laboratories

(*) all the information are similar for the mentioned companies

Chapter 7: Conclusion

Chapter 8: Appendix

8.1. List of tables

8.2. Assumptions

8.3. Research and methodology

8.4. About Netscribes Inc.

Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research. Disclaimer: The report will be delivered within 5-7 business days post payment confirmation

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

1. Quest Diagnostics

2. Hologic Inc.

3. Qiagen

4. F. Hoffmann-La Roche AG

5. Abbott Laboratories